Horizon Pharma (HZNP) Announces Presentation of Significant Retrospective KRYSTEXXA Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
November 14, 2016 7:00 AM ESTDUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that a retrospective analysis of data from previous pivotal, randomized KRYSTEXXA® (pegloticase) clinical trials demonstrate that refractory chronic gout patients defined as non-responders based on serum uric acid levels in the trials still achieved significant clinical benefit despite a loss of response in uric acid levels.  These data... More
